Skip to content

24/7 dementia helpline 800-272-3900

Dementia Today

Israel’s Neuronix offers new Alzheimer’s treatment

Dementia TodayPublished November 4, 20123 min read

Key points

  • Israel-based Neuronix, which has developed a non-invasive medical device to help to treat Alzheimer’s disease, expects the system to be approved by the U.S.
  • “You stimulate the brain on a biological level as well as on a cognitive level,” Neuronix CEO Eyal Baror told Reuters, saying this double approach created longer-lasting benefits.
  • The system is in trials at Harvard Medical School/Beth Israel Deaconess Medical Centre.
  • “The application in Alzheimer’s disease and in combination with cognitive training is novel,” Pascual-Leono said in a phone interview from Boston.

Israel-based Neuronix, which has developed a non-invasive medical device to help to treat Alzheimer’s disease, expects the system to be approved by the U.S. Food & Drug Administration in late 2014.

The device, which combines electromagnetic stimulation with computer-based cognitive training, is already approved for use in Europe, Israel and several Asian countries. In Singapore it is approved for clinical trial use and the application for registration of the product is still under evaluation.

“You stimulate the brain on a biological level as well as on a cognitive level,” Neuronix CEO Eyal Baror told Reuters, saying this double approach created longer-lasting benefits.

The device, which consists of a chair containing an electronic system and software in the back and a coil placed at the head, has been tested on mild to moderate Alzheimer’s patients who suffer from dementia but are not totally dependent.

The system is in trials at Harvard Medical School/Beth Israel Deaconess Medical Centre. Patients are treated for one hour a day, five days a week over six weeks.

“We see improvement lasting for 9-12 months and the good thing is that patients can return and undergo treatment again,” Baror said. “If out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it’s a lot.”

According to Alvaro Pascual-Leone, director of the hospital’s Berenson-Allen Centre for Non-invasive Brain Stimulation, brain stimulation – or transcranial magnetic stimulation – involves a very low current applied to a specific part of the brain and is approved by the FDA for treatment of a variety of ailments and diagnostic applications.

“The application in Alzheimer’s disease and in combination with cognitive training is novel,” Pascual-Leono said in a phone interview from Boston.

About 20 percent of patients experience a mild headache but there are no long-term negative effects, he said.

Pascual-Leone, who is principal investigator in the Harvard trial, said that of 12 patients in the study, six received the real treatment and all showed cognitive improvement. Their improvement was significantly more than the average seen in patients taking just medication, he said.

The study’s results will be submitted for publication in the coming weeks and a follow-up study on 30 patients is planned.

Neuronix received European approval several months ago and has installations in the UK and Germany. In Israel, a few dozen patients are being treated with the device.

The U.S. trials are expected to run till the end of 2013. Neuronix is also running a trial in Israel for pre-Alzheimer’s patients.

The company expects to sell half a dozen systems in the second half of 2012 and three dozen in 2013. In Israel, the treatment costs $6,000.

“Our target for becoming profitable is in parallel to entering the U.S. market around 2015,” Baror said.

Neuronix has raised $8 million from private individuals as well as in grants from the Israeli Chief Scientist’s Office and is exploring options to raise more money in the coming year, including the possibility of going public.

(This version of the October 24 story corrects paragraph two that company corrects to say that in Singapore, device is approved for clinical trial use and its application for registration of the product is under evaluation, not that device is approved for commercial use.)

###

By Tova Cohen

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. If a person with dementia is missing, injured or in danger, call 911 or your local emergency number.

Filed underDementia News

Worried about memory changes?

Normal aging, or an early warning sign?

Ten common changes, each set beside what is typical with age. Tick what you have noticed and see what to do next.

Open the 10-sign checklist

Getting help

Sudden changes are not just the dementia.

Dementia usually changes slowly. A sharp change over hours or days can mean an infection, delirium, a stroke or a medication problem, and needs a doctor the same day. Call 911 or your local emergency number if you see any of these:

  • Confusion that comes on suddenly, over hours or days
  • Face drooping, arm weakness or slurred speech
  • A fall, a head injury or new severe pain
  • Very drowsy or hard to wake

The free Alzheimer’s Association Helpline answers questions about memory loss, diagnosis and caregiving, day and night, in more than 200 languages (US).

If someone with dementia is missing

  1. STEP 115 minSearch close by firstCheck the house, garden, car and the places the person often walks to. Don’t spend longer than about 15 minutes.
  2. STEP 2911Then call for helpTell the operator the person has dementia and is a vulnerable adult. Police treat this as urgent.
  3. STEP 3PhotoHave details readyA recent photo, what they were wearing, medical conditions and places they used to live or work.

Based on Alzheimer’s Association guidance on wandering. Outside the US, call your local emergency number.